EUDA Health Holdings Limited announced the launch of a new stem cell therapy platform and the opening of its first longevity clinic in Shenzhen on December 23 2025. The platform combines the company’s proprietary induced pluripotent stem cell (iPSC) technology, acquired through a planned acquisition of GO POSB Organoids, with T‑cell immunotherapies licensed from Shenzhen Inno Immune and advanced stem‑cell therapies sourced from two Japanese partners, including Japan Early Light Medical Corporation.
The upgraded cGMP facility in Shenzhen will support large‑scale iPSC expansion, stem‑cell preparation, and the development of treatments focused on immune health, skin health, and healthy aging. The facility upgrade is part of EUDA’s strategy to build an end‑to‑end regenerative ecosystem, enabling the company to supply both B2B iPSC solutions to healthcare providers and biotech developers and to launch off‑the‑shelf products for wellness and aesthetics markets.
By establishing the Shenzhen Longevity Clinic, EUDA becomes the first regional provider to offer a full suite of Japanese longevity healthcare technologies. The clinic is positioned to capture a growing market for preventive and regenerative medicine in Asia, where an aging population is driving demand for longevity solutions. The launch also signals EUDA’s intent to integrate its technology portfolio into a comprehensive service offering, potentially creating new revenue streams and strengthening its competitive position against other longevity players.
CEO Alfred Lim said the launch marks a defining moment for EUDA, stating that the integrated platform and clinic “build a comprehensive, end‑to‑end regenerative ecosystem” that will allow the company to capitalize on the fast‑growing longevity sector. Lim emphasized that the partnership with Japanese experts and the expansion into China are key to scaling the company’s technology and reaching a broader patient base.
The announcement reflects EUDA’s broader strategy of pursuing high‑impact collaborations and expanding its geographic footprint. The company’s focus on iPSC technology, T‑cell therapies, and Japanese longevity expertise positions it to benefit from increasing demand for regenerative solutions and to diversify its product pipeline beyond traditional biotech offerings.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.